Table 1.
Overview of human trials of HER2 targeting non-approved immunotherapeutic conjugates, their composition and their current state of development. Status of April 2020
| ADC | Antibody | Payload | Trial no. | Phase | Patients | First posted | Status |
|---|---|---|---|---|---|---|---|
| BAT8001 | Trastuzumab | Maytansine derivative | NCT04189211 | I | 30 | 12/2019 | Active, not recruiting |
| NCT04151329 | I / II | 72 | 11/2019 | Enrolling by invitation | |||
| NCT04185649 | III | 410 | 12/2019 | Active, not recruiting | |||
| [vic-] Trastuzumab Duocarmycin (SYD985) | Trastuzumab | vc-seco-DUBA | NCT02277717 | I | 185 | 10/2014 | Completed |
| NCT04235101 | I | 120 | 01/2020 | Recruiting | |||
| NCT04205630 | II | 60 | 12/2019 | Recruiting | |||
| NCT03262935 | III | 345 | 08/2017 | Recruiting | |||
| Hertuzumab Vedotin (RC-48) | Hertuzumab | Monomethylauristatin E | NCT02881190 | I | 57 | 08/2016 | Completed |
| NCT02881138 | I | 50 | 08/2016 | Recruiting | |||
| NCT04311034 | I | 36 | 03/2020 | Recruiting | |||
| NCT03052634 | I / II | 90 | 02/2017 | Recruiting | |||
| NCT04264936 | I / II | 36 | 02/2020 | Recruiting | |||
| NCT04329429 | II | 57 | 04/2020 | Recruiting | |||
| NCT03809013 | II | 60 | 01/2019 | Recruiting | |||
| NCT04073602 | II | 18 | 08/2019 | Recruiting | |||
| NCT03556345 | II | 127 | 06/2018 | Active, not recruiting | |||
| NCT03500380 | II | 228 | 04/2018 | Recruiting | |||
| MM-302 | PEGylated antibody | Liposomal doxorubicin | NCT01304797 | I | 75 | 02/2011 | Unknown |
| NCT02213744 | II / III | 113 | 08/2014 | Terminated | |||
| ARX788 | Anti HER2 antibody | Amberstatin269 | NCT03255070 | I | 60 | 08/2017 | Recruiting |
| XMT-1522 | HT-19 | Auristatin F-hydroxypropylamide | NCT02952729 | I | 120 | 11/2016 | Active, not recruiting |
| MEDI4276 | bi-paratopic antibody | AZ13599185 | NCT02576548 | I / II | 47 | 10/2015 | Completed |
| DHES0815A | Trastuzumab derivative | pyrrolobenzodiazepine | NCT03451162 | I | 14 | 03/2018 | Active, not recruiting |
| BDC-1001 | Trastuzumab | TLR7/8 agonist | NCT04278144 | I | 390 | 02/2020 | Recruiting |
| ALT-P7 (HM2-MMAE) | HM2 | monomethylauristatin E | NCT03281824 | I | 30 | 09/2017 | Recruiting |
| ADCT-502 | Trastuzumab | Tesirine | NCT03125200 | I | 21 | 04/2017 | Terminated |
| PF-06804103 | Anti HER2 antibody | Auristatin-0101 | NCT03284723 | I | 124 | 09/2017 | Recruiting |